Serious Allergic Reactions: Immediately interrupt infusion and permanently discontinue the tositumomab and iodine I 131 tositumomab therapeutic regimen for serious allergic reactions. Prolonged and severe cytopenias occur in most patients. Tositumomab and iodine I 131 tositumomab should not be administered to patients with greater than 25% lymphoma marrow involvement, platelet count less than 100,000 cells/mm(3), or neutrophil count less than 1500 cells/mm(3). The tositumomab and iodine I 131 tositumomab therapeutic regimen is supplied only to certified healthcare professionals. Follow institutional radiation safety practices and applicable federal guidelines to minimize radiation exposure to household contacts and medical staff .Intravenous route(Solution)
Serious Allergic Reactions: Immediately interrupt infusion and permanently discontinue the tositumomab and iodine I 131 tositumomab therapeutic regimen for serious allergic reactions. Prolonged and severe cytopenias occur in most patients. Tositumomab and iodine I 131 tositumomab should not be administered to patients with greater than 25% lymphoma marrow involvement, platelet count less than 100,000 cells/mm(3), or neutrophil count less than 1500 cells/mm(3). The tositumomab and iodine I 131 tositumomab therapeutic regimen is supplied only to certified healthcare professionals. Follow institutional radiation safety practices and applicable federal guidelines to minimize radiation exposure to household contacts and medical staff .
Tositumomab and iodine I 131 tositumomab combination regimen is used to treat patients with CD20-positive, relapsed or refractory non-Hodgkin's lymphoma. It is also given to patients with non-Hodgkin's lymphoma who already have received rituximab.
This medicine is to be given only by or under the immediate supervision of your doctor.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Appropriate studies have not been performed on the relationship of age to the effects of Bexxar® regimen in the pediatric population. Safety and efficacy have not been established.
Although appropriate studies on the relationship of age to the effects of Bexxar® regimen have not been performed in the geriatric population, no geriatric-specific problems have been documented to date.
|All Trimesters||D||Studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy in a life threatening situation or a serious disease, may outweigh the potential risk.|
Breast-feedingIodine I 131 Tositumomab
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.Tositumomab
Studies in women breastfeeding have demonstrated harmful infant effects. An alternative to this medication should be prescribed or you should stop breastfeeding while using this medicine.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
Other medical problems
The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:
Medicines used to treat cancer are very strong and can have many side effects. Before receiving this medicine, make sure you understand all the risks and benefits. It is important for you to work closely with your doctor during your treatment.
A doctor will give you this medicine in a hospital or cancer treatment center. This medicine is given through a needle placed in one of your veins.
Bexxar® therapeutic regimen consists of 2 separate components (tositumomab and iodine I 131 tositumomab) which are given in 2 separate steps 7 to 14 days apart. You may also receive medicines (e.g., acetaminophen, diphenhydramine) to help prevent possible allergic reactions to the injection.
It is very important that your doctor check you closely while you are receiving this medicine. This is to make sure that this medicine is working properly. Blood tests may be needed to check for unwanted effects.
Using this medicine while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant. You should not become pregnant while you are receiving this medicine and for 12 months after stopping it. Male patients should also use effective contraception to prevent pregnancy while receiving this medicine and for 12 months after stopping it. Tell your doctor right away if you become pregnant while using the medicine.
This medicine may cause serious allergic reactions, including anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Call your doctor right away if you have a rash, itching, fever or chills, lightheadedness or dizziness, nausea, trouble breathing, or any swelling of your hands, face, mouth, or throat during treatment or within 48 hours receiving this medicine.
Tositumomab and iodine I 131 tositumomab regimen can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. It can also lower the number of platelets, which are necessary for proper blood clotting. If this occurs, there are certain precautions you can take, especially when your blood count is low, to reduce the risk of infection or bleeding:
While using this medicine, you may be exposed to radiation. Talk with your doctor if you have concerns about this.
This medicine may increase your risk for certain types of cancer or thyroid problems. Talk with your doctor about these risks.
While you are being treated with tositumomab and iodine I 131 tositumomab regimen, and after you stop treatment with it, do not have any immunizations (live vaccines) without your doctor's approval. Tositumomab and iodine I 131 tositumomab may lower your body's resistance and there is a chance you might get the infection the immunization is meant to prevent.
If you plan to have children, talk with your doctor before using this medicine. Some men and women using this medicine have become infertile (unable to have children).
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.